keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/28919773/sickle-cell-retinopathy-improving-care-with-a-multidisciplinary-approach
#1
REVIEW
Farid Menaa, Barkat Ali Khan, Bushra Uzair, Abder Menaa
Sickle cell retinopathy (SCR) is the most representative ophthalmologic complication of sickle cell disease (SCD), a hemoglobinopathy affecting both adults and children. SCR presents a wide spectrum of manifestations and may even lead to irreversible vision loss if not properly diagnosed and treated at the earliest. Over the past decade, multidisciplinary research developments have focused upon systemic, genetic, and ocular risk factors of SCR, enabling the clinician to better diagnose and manage these patients...
2017: Journal of Multidisciplinary Healthcare
https://www.readbyqxmd.com/read/28913517/intravitreal-injection-of-ziv-aflibercept-in-the-treatment-of-choroidal-and-retinal-vascular-diseases
#2
Kamran HodjatJalali, Shiva Mehravaran, Hooshang Faghihi, Hassan Hashemi, Pegah Kazemi, Hadith Rastad
PURPOSE: To investigate the short-term outcomes after intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. METHODS: Thirty-four eyes of 29 patients with age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO) received a single dose intravitreal injection of 0.05 ml ziv-aflibercept (1.25 mg). Visual acuity, spectral domain optical coherence tomography (SD-OCT) activity, and possible side effects were assessed before and at 1 week and 1 month after the intervention...
September 2017: Journal of Current Ophthalmology
https://www.readbyqxmd.com/read/28902097/retinal-microvasculature-and-visual-acuity-after-intravitreal-aflibercept-in-eyes-with-central-retinal-vein-occlusion-an-optical-coherence-tomography-angiography-study
#3
Andrew Winegarner, Taku Wakabayashi, Chikako Hara-Ueno, Tatsuhiko Sato, Caleb Busch, Yoko Fukushima, Kaori Sayanagi, Kentaro Nishida, Hirokazu Sakaguchi, Kohji Nishida
PURPOSE: To investigate vascular perfusion and foveal avascular zone area in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) after intravitreal aflibercept therapy in central retinal vein occlusion eyes and their association with best-corrected visual acuity. METHODS: Thirty-five subjects with central retinal vein occlusion and macular edema were evaluated. After macular edema resolution following intravitreal aflibercept, subjects underwent optical coherence tomography angiography to measure SCP and DCP perfusion and the foveal avascular zone within a 3 × 3-mm area...
September 7, 2017: Retina
https://www.readbyqxmd.com/read/28900543/switching-to-aflibercept-in-diabetic-macular-edema-not-responding-to-ranibizumab-and-or-intravitreal-dexamethasone-implant
#4
Antoine Herbaut, Franck Fajnkuchen, Lise Qu-Knafo, Sylvia Nghiem-Buffet, Bahram Bodaghi, Audrey Giocanti-Auregan
PURPOSE: To assess short-term functional and anatomical outcomes of refractory diabetic macular edema (DME) following a switch from ranibizumab or dexamethasone to aflibercept. METHODS: We included retrospectively eyes with persistent DME after at least 3 ranibizumab and/or one dexamethasone implant intravitreal injections (IVI). The primary endpoint was the mean change in visual acuity (VA) at month 6 (M6) after switching. RESULTS: Twenty-five eyes were included...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28898873/two-year-outcomes-of-a-treat-and-extend-regimen-using-intravitreal-aflibercept-injections-for-typical-age-related-macular-degeneration
#5
Arisa Ito, Hidetaka Matsumoto, Masahiro Morimoto, Kensuke Mimura, Hideo Akiyama
PURPOSE: The aim of this study was to evaluate the efficacy of a treat-and-extend (TAE) regimen using intravitreal injection of aflibercept (IVA) for typical age-related macular degeneration (tAMD). METHODS: We retrospectively studied 61 treatment-naïve eyes with tAMD. Best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), number of injections, and complications during 2 years were evaluated. RESULTS: BCVA significantly improved by on average 0...
September 13, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28894355/erratum-intravitreal-aflibercept-for-choroidal-neovascularization-associated-with-chorioretinitis-a-pilot-study-corrigendum
#6
(no author information available yet)
[This corrects the article on p. 1315 in vol. 11, PMID: 28769551.].
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28883712/integrated-results-from-the-copernicus-and-galileo-studies
#7
Amelie Pielen, W Lloyd Clark, David S Boyer, Yuichiro Ogura, Frank G Holz, Jean-Francois Korobelnik, Brigitte Stemper, Friedrich Asmus, Kay D Rittenhouse, Christiane Ahlers, Robert Vitti, Namrata Saroj, Oliver Zeitz, Julia A Haller
OBJECTIVES: To report on the efficacy and safety of intravitreal aflibercept in patients with macular edema secondary to central retinal vein occlusion (CRVO) in an integrated analysis of COPERNICUS and GALILEO. PATIENTS AND METHODS: Patients were randomized to receive intravitreal aflibercept 2 mg every 4 weeks or sham injections until week 24. From week 24 to week 52, all intravitreal aflibercept-treated patients in both studies and sham-treated patients in COPERNICUS were eligible to receive intravitreal aflibercept based on prespecified criteria...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28852904/-what-should-i-inject-next-challenging-treatment-decisions-in-the-multiple-anti-vegf-a-review-of-publications-exploring-anti-vegf-switching-for-namd
#8
Joseph Pikkel, Shira Attas
PURPOSE: The purpose of our work was to collate information from studies published to date focusing on switching in anti-VEGF therapy and describe the currently available data on anti-VEGF switching in nAMD. METHODS: A PubMed search of published articles from January 2010 to January 2017 was conducted. Published studies were compared in parameters of sample size, reason for switch, duration of follow-up, and switch outcome (functional and anatomical). RESULTS: Our search revealed 31 relevant publications...
August 29, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28851779/protocol-for-a-randomised-double-masked-sham-controlled-phase-4-study-on-the-efficacy-safety-and-tolerability-of-intravitreal-aflibercept-monotherapy-compared-with-aflibercept-with-adjunctive-photodynamic-therapy-in-polypoidal-choroidal-vasculopathy-the-atlantic
#9
João Pedro Marques, Cláudia Farinha, Miguel Ângelo Costa, Ângela Ferrão, Sandrina Nunes, Rufino Silva
PURPOSE: The purpose of this study is to compare the efficacy and safety of intravitreal aflibercept (IVA) with sham photodynamic therapy (sPDT) versus IVA with verteporfin PDT (vPDT) in a Caucasian population with treatment-naive polypoidal choroidal vasculopathy (PCV), enrolling into a treat and extend (T&E) regimen. METHODS AND ANALYSIS: Randomised, double-masked, sham-controlled, multicentre phase 4 investigator-driven clinical trial. The primary outcomes are (1) change in best-corrected visual acuity (BCVA) from baseline and (2) polyp regression at week 52, assessed by indocyanine green angiography (ICGA)...
August 28, 2017: BMJ Open
https://www.readbyqxmd.com/read/28844343/inclusion-of-elderly-or-frail-patients-in-randomized-controlled-trials-of-targeted-therapies-for-the-treatment-of-metastatic-colorectal-cancer-a-systematic-review
#10
REVIEW
Amandine Gouverneur, Francesco Salvo, Driss Berdaï, Nicholas Moore, Annie Fourrier-Réglat, Pernelle Noize
Treatment of metastatic colorectal cancer (mCRC) has been modified since the launching of targeted therapies. Colorectal cancer (CRC) is common in elderly patients; their representation in randomized controlled trials (RCTs) is thus crucial. This study aimed to evaluate and quantify the inclusion of elderly/frail patients in RCTs of targeted therapies in mCRC. A systematic review using Medline, Scopus, Cochrane Database and ISI Web of Science was performed to identify all phase II/III RCTs of bevacizumab, cetuximab, panitumumab, regorafenib and aflibercept in mCRC until January 2015...
August 22, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28841584/contamination-of-anti-vegf-drugs-for-intravitreal-injection-how-do-repackaging-and-newly-developed-syringes-affect-the-amount-of-silicone-oil-droplets-and-protein-aggregates
#11
Marc Schargus, Benjamin P Werner, Gerd Geerling, Gerhard Winter
PURPOSE: The particle counts and the nature of particles of three different antivascular endothelial growth factor agents (VEGF) in different containers in a laboratory setting were compared. METHODS: Original prefilled ranibizumab glass syringes, original vials with aflibercept, and repacked ready-to-use plastic syringes with bevacizumab from a compounding pharmacy and a compounding company (CC) were analyzed. Particle counts and size distributions were quantified by different particle characterization methods (nephelometry, light obscuration, Micro-Flow Imaging, nanotracking analysis, resonant mass measurement)...
August 21, 2017: Retina
https://www.readbyqxmd.com/read/28837425/aflibercept-bevacizumab-or-ranibizumab-for-diabetic-macular-oedema-recent-clinically-relevant-findings-from-drcr-net-protocol-t
#12
Sophie Cai, Neil M Bressler
PURPOSE OF REVIEW: The aim of this study was to provide clinically relevant findings from the DRCR.net Protocol T, a multicentre randomized clinical trial comparing intravitreous aflibercept, repackaged (compounded) bevacizumab and ranibizumab for vision-impairing centre-involved diabetic macular oedema (DME). RECENT FINDINGS: At 1 year, all three antivascular endothelial growth factor (anti-VEGF) drugs, on average, improved visual acuity. There was no difference among drugs in mean change in visual acuity from baseline among eyes with baseline Snellen equivalent visual acuity of 20/32 to 20/40, whereas aflibercept yielded superior vision outcomes among eyes with baseline visual acuity of 20/50 to 20/320...
August 23, 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/28829220/neovascular-age-related-macular-degeneration-disease-quiescence-with-visual-acuity-stability-in-a-subgroup-of-patients-following-prn-treatment
#13
Greg D Fliney, Leonid M Zukin, Curtis Hagedorn
PURPOSE: This study evaluates long-term visual acuity (VA) outcomes in patients with prolonged clinically quiescent neovascular age-related macular degeneration (AMD) after treatment with a pro re nata (PRN) regimen of anti-vascular endothelial growth factor agents (bevacizumab, ranibizumab, and/or aflibercept). METHODS: This retrospective study analyzes VA changes in 105 eyes from 72 patients with a period of AMD disease quiescence (determined by retinal examination) not requiring treatment for at least 180 days...
August 22, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28820850/ultrasonographic-findings-in-the-vitreous-of-patients-with-age-related-macular-degeneration-treated-with-intravitreal-anti-vascular-endothelial-growth-factor-injections
#14
Tamara Mato-Gondelle, Manuel F Bande, Laura Paniagua, María J Rodríguez-Cid, Maximino Abraldes, Maribel Fernández, María J Blanco-Teijeiro, Antonio Piñeiro
PURPOSE: We aimed to assess the relationship of repeated intravitreal injection of anti-vascular endothelial growth factor, the main treatment for exudative age-related macular degeneration, with changes in vitreous ultrasonographic findings in patients with age-related macular degeneration. METHODS: We retrospectively collected data from 41 patients (41 age-related macular degeneration eyes, 41 control eyes) on age, sex, number of injections, and type of anti-vascular endothelial growth factor (ranibizumab, aflibercept)...
August 16, 2017: Retina
https://www.readbyqxmd.com/read/28820848/ranibizumab-and-aflibercept-for-the-treatment-of-pigment-epithelial-detachment-in-neovascular-age-related-macular-degeneration-data-from-an-observational-study
#15
Anagha Vaze, Vuong Nguyen, Vincent Daien, Jennifer J Arnold, Stephanie H Young, Chui M Cheung, Ecosse Lamoureux, Mayuri Bhargava, Daniel Barthelmes, Mark C Gillies
PURPOSE: To assess the effect of intravitreal ranibizumab and aflibercept on retinal pigment epithelial detachment (RPED) in patients with neovascular age-related macular degeneration. METHODS: This was a retrospective analysis of data from a prospectively designed and implemented clinical audit. Analysis included change in RPED dimensions and visual acuity in 92/233 treatment-naive eyes with neovascular age-related macular degeneration and RPED 6 months after treatment with either aflibercept or ranibizumab...
August 16, 2017: Retina
https://www.readbyqxmd.com/read/28820169/aflibercept-for-recurrent-or-recalcitrant-polypoidal-choroidal-vasculopathy-in-indian-eyes-early-experience
#16
Aditya Bansal, Muna Bhende, Tarun Sharma, Pramod Bhende, Suchetana Mukherjee
Treatment guidelines for symptomatic polypoidal choroidal vasculopathy (PCV) have been described, but the management of recurrent or recalcitrant PCV is a challenge. The newer anti-vascular endothelial growth factor: aflibercept has shown promise in the treatment of both treatment naive and recalcitrant PCV in studies outside India. We present the minimum 6 months results of intravitreal aflibercept in recurrent and recalcitrant PCV in Indian eyes after multiple injections of bevacizumab/ranibizumab with or without photodynamic therapy...
August 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28818671/incidence-and-risk-of-cardiotoxicity-in-cancer-patients-treated-with-targeted-therapies
#17
REVIEW
Matteo Santoni, Federico Guerra, Alessandro Conti, Alessandra Lucarelli, Silvia Rinaldi, Laura Belvederesi, Alessandro Capucci, Rossana Berardi
BACKGROUND: Cardiotoxicityis a serious side effect of molecularly targeted agents. The purpose of this study was to evaluate the incidence and Relative Risk (RR) of developing all-grade and high-grade cardiotoxicity in patients with solid tumors receiving targeted agents through a revised meta-analysis of available clinical trials. METHODS: The scientific literature regarding cardiotoxicity was extensively analyzed using MEDLINE, PubMed, Embase and Cochrane Central Register of Controlled Trials (CENTRAL)...
September 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28816730/intravitreal-injection-of-aflibercept-in-patients-with-polypoidal-choroidal-vasculopathy-a-3-year-follow-up
#18
Maiko Maruyama-Inoue, Shimpei Sato, Shin Yamane, Kazuaki Kadonosono
PURPOSE: To compare the 3-year follow-up results of intravitreal injections of aflibercept between fixed dosing (FD) regimen and a pro re nata (PRN) regimen after three initial monthly doses for the treatment of polypoidal choroidal vasculopathy and to analyze factors influencing improvement in visual acuity. METHODS: We retrospectively studied all treatment-naive patients with polypoidal choroidal vasculopathy who were scheduled to receive intravitreal aflibercept injections FD or PRN after induction treatment between March 2013 and May 2014...
August 14, 2017: Retina
https://www.readbyqxmd.com/read/28814412/long-term-outcomes-with-as-needed-aflibercept-in-diabetic-macular-oedema-2-year-outcomes-of-the-endurance-extension-study
#19
Charles C Wykoff, William C Ou, Rahul N Khurana, David M Brown, W Lloyd Clark, David S Boyer
BACKGROUND/AIMS: To evaluate the efficacy and safety of individualised 2.0 mg intravitreal aflibercept retreatment for diabetic macular oedema (DME) through the fifth year of management. METHODS: This is a phase IV, 2-year, open-label extension study. Sixty patients completing the 3-year VISTA DME (Study of Intravitreal Aflibercept Injection in Patients With Diabetic Macular Edema) phase III trial enrolled in the ENDURANCE (Long-Term Efficacy and Safety of Intravitreal Aflibercept for the Treatment of DME in Subjects Who Completed the VISTA DME Trial) extension study...
August 16, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28810842/erratum-to-short-term-efficacy-of-intravitreal-aflibercept-injections-for-retinal-angiomatous-proliferation
#20
Hung-Da Chou, Wei-Chi Wu, Nan-Kai Wang, Lan-Hsin Chuang, Kuan-Jen Chen, Chi-Chun Lai
No abstract text is available yet for this article.
August 15, 2017: BMC Ophthalmology
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"